AstraZeneca Pharma India Ltd receives permission for sale and distribution of Trastuzumab deruxtecan

AstraZeneca Pharma India Limited has received a permission in Form CT-20 to Import for sale and distribution of Trastuzumab deruxtecan (Enhertu) 100mg/5mL vial lyophilized powder for concentrate for solution for infusion from the Central Drugs Standard Control Organisation, Directorate General of Health Services, Government of India.

Through this approval, Trastuzumab deruxtecan (Enhertu) is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received a prior anti-HER2-based regimen.

The receipt of this permission paves way for the launch of Trastuzumab deruxtecan (Enhertu) solution of 100mg/5mL in India for the specified indication, subject to the receipt of related statutory approvals, if any.

Shares of AstraZeneca Pharma India Limited was last trading in BSE at Rs. 3163.95 as compared to the previous close of Rs. 3178.80. The total number of shares traded during the day was 63 in over 26 trades.

The stock hit an intraday high of Rs. 3191.60 and intraday low of 3161.50. The net turnover during the day was Rs. 199755.00.

Source : Equity Bulls

Keywords

AstraZenecaPharmaIndia INE203A01020 Permission Import Sale Distribution Trastuzumabderuxtecan